Company
Akebia Therapeutics, Inc. (AKBA)
Standardized SEC financial data for Akebia Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001517022 · NASDAQ · Pharmaceutical Preparations.
Gross margin
83.3%
Operating margin
9.9%
Net margin
-2.3%
Revenue growth (YoY)
47.5%
Return on equity
-16.4%
Free cash flow
$67.7M
Debt / equity
1.48×
Current ratio
1.55×
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $294.6M | $211.7M | $292.5M | $194.6M | $160.2M | $236.2M |
| Cost of revenue |
Balance sheet
| USD | FY2022 | FY2022 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | $93.2M | $44.6M | $53.5M | $186.5M |
| Inventory |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$110.4M | -$253.0M | -$73.2M | -$23.4M | -$40.7M | $68.0M |
| Capital expenditures |
Get AKBA data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/AKBA/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/AKBA/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"